image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IS
$ 8.36
0.483 %
$ 2.52 B
Market Cap
-9.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALVO stock under the worst case scenario is HIDDEN Compared to the current market price of 8.36 USD, Alvotech is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALVO stock under the base case scenario is HIDDEN Compared to the current market price of 8.36 USD, Alvotech is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALVO stock under the best case scenario is HIDDEN Compared to the current market price of 8.36 USD, Alvotech is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALVO

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
490 M REVENUE
435.56%
69.6 M OPERATING INCOME
119.63%
-232 M NET INCOME
57.98%
-237 M OPERATING CASH FLOW
24.13%
-18.9 M INVESTING CASH FLOW
59.28%
297 M FINANCING CASH FLOW
-1.33%
151 M REVENUE
46.96%
13.5 M OPERATING INCOME
5.85%
-67 M NET INCOME
-487.79%
-39.2 M OPERATING CASH FLOW
45.28%
-31.1 M INVESTING CASH FLOW
-136.47%
4.3 M FINANCING CASH FLOW
-97.24%
Balance Sheet Alvotech
image
Current Assets 455 M
Cash & Short-Term Investments 51.4 M
Receivables 252 M
Other Current Assets 152 M
Non-Current Assets 766 M
Long-Term Investments 0
PP&E 410 M
Other Non-Current Assets 357 M
4.21 %20.61 %12.43 %33.55 %29.20 %Total Assets$1.2b
Current Liabilities 193 M
Accounts Payable 67.1 M
Short-Term Debt 42.2 M
Other Current Liabilities 84.1 M
Non-Current Liabilities 1.44 B
Long-Term Debt 1.15 B
Other Non-Current Liabilities 293 M
4.11 %5.14 %70.25 %17.91 %Total Liabilities$1.6b
EFFICIENCY
Earnings Waterfall Alvotech
image
Revenue 490 M
Cost Of Revenue 185 M
Gross Profit 304 M
Operating Expenses 235 M
Operating Income 69.6 M
Other Expenses 302 M
Net Income -232 M
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)490m(185m)304m(235m)70m(302m)(232m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
62.16% GROSS MARGIN
62.16%
14.22% OPERATING MARGIN
14.22%
-47.35% NET MARGIN
-47.35%
56.17% ROE
56.17%
-18.98% ROA
-18.98%
6.94% ROIC
6.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alvotech
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)202020202021202120222022202320232024202420252025
Net Income -232 M
Depreciation & Amortization 31.3 M
Capital Expenditures -57 M
Stock-Based Compensation 7.63 M
Change in Working Capital -289 M
Others 156 M
Free Cash Flow -294 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alvotech
image
Wall Street analysts predict an average 1-year price target for ALVO of $18.5 , with forecasts ranging from a low of $10 to a high of $22 .
ALVO Lowest Price Target Wall Street Target
10 USD 19.62%
ALVO Average Price Target Wall Street Target
18.5 USD 121.29%
ALVO Highest Price Target Wall Street Target
22 USD 163.16%
Price
Max Price Target
Min Price Target
Average Price Target
222220201818161614141212101088Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Alvotech
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
New Strong Sell Stocks for April 17th AIRS, XOM and ALVO have been added to the Zacks Rank #5 (Strong Sell) List on April 17, 2025. zacks.com - 2 weeks ago
This Is a Test From GlobeNewswire This is a test from GlobeNewswire. Readers are advised to disregard. globenewswire.com - 1 month ago
Alvotech (ALVO) Q4 2024 Earnings Call Transcript Alvotech (NASDAQ:ALVO ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph McClellan - Chief Scientific Officer Joel Morales - Chief Financial Officer Benedikt Stefannson - Vice President, Investor Relations Conference Call Participants Ashwani Verma - UBS Operator Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call. seekingalpha.com - 1 month ago
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. globenewswire.com - 1 month ago
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. globenewswire.com - 1 month ago
Alvotech Reports Record Results for 2024 and Provides Business Update Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on March 27, 2024, at 8:00 am ET (12:00 pm GMT). globenewswire.com - 1 month ago
Alvotech Reports Record Results for 2024 and Provides Business Update REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on March 27, 2024, at 8:00 am ET (12:00 pm GMT). globenewswire.com - 1 month ago
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair in 2024 were about USD $4.4 billion [1]. globenewswire.com - 1 month ago
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair in 2024 were about USD $4.4 billion [1]. globenewswire.com - 1 month ago
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other pre-clinical assets and will focus on the commercialization of this portfolio. Alvotech also announced that it intends to explore the possibility of a listing of Swedish Depository Receipts (SDR), equity share equivalents, on Nasdaq Stockholm, in the future. globenewswire.com - 1 month ago
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market globenewswire.com - 1 month ago
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review. zacks.com - 1 month ago
8. Profile Summary

Alvotech ALVO

image
COUNTRY IS
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 2.52 B
Dividend Yield 0.00%
Description Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Contact Saemundargata 15-19, Reykjavik, 102 https://www.alvotech.com
IPO Date June 16, 2022
Employees 1012
Officers Mr. Giedrius Zunda Chief Technical Officer Mr. Anil Okay Chief Commercial Officer Mr. Faysal Kalmoua Chief Operating Officer & Director Mr. Joseph E. McClellan Chief Scientific Officer Ms. Tanya Zharov General Counsel Mr. Robert Wessman Chief Executive Officer, Founder & Executive Chairman Mr. Anthony M. Maffia III Chief Regulatory Affairs Officer Mr. Benedikt Stefansson Vice President of Investor Relations and Global Communications Ms. Jenny Sif Steingrimsdottir Vice President of People & Culture Mr. Joel Morales Chief Financial Officer